Volume | 4,323 |
|
|||||
News | - | ||||||
Day High | 1.1999 | Low High |
|||||
Day Low | 1.1601 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Bright Minds Biosciences Inc | DRUG | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.19 | 1.1601 | 1.1999 | 1.1999 | 1.17 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
51 | 4,323 | $ 1.18 | $ 5,100 | - | 1.09 - 6.44 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:29:32 | 5 | $ 1.22 | USD |
Bright Minds Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.36M | 4.46M | - | 0 | -7.37M | -1.65 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Bright Minds Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DRUG Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.28 | 1.31 | 1.09 | 1.19 | 29,538 | -0.06 | -4.69% |
1 Month | 1.82 | 1.9499 | 1.09 | 1.42 | 25,348 | -0.60 | -32.97% |
3 Months | 1.72 | 2.39 | 1.09 | 1.80 | 27,956 | -0.50 | -29.07% |
6 Months | 1.58 | 2.39 | 1.09 | 1.64 | 27,807 | -0.36 | -22.78% |
1 Year | 2.20 | 6.44 | 1.09 | 3.37 | 362,314 | -0.98 | -44.55% |
3 Years | 44.75 | 44.75 | 1.09 | 10.36 | 1,546,199 | -43.53 | -97.27% |
5 Years | 44.75 | 44.75 | 1.09 | 10.36 | 1,546,199 | -43.53 | -97.27% |
Bright Minds Biosciences Description
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin. |